← Leaderboards
John A Moss
Auritec Pharmaceuticals, Inc.
$9,543,203
Attributed
$14,038,515
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,038,515 · 6
By mechanism
R01$9,572,336 · 2
U19$1,801,265 · 1
R33$1,434,029 · 1
R61$1,019,023 · 1
R41$211,862 · 1
Top collaborators
- Sanjay Ram10 shared
- Peter A. Rice5 shared
- Keith Wycoff5 shared
- Thomas J. Smith1 shared
Most similar at Auritec Pharmaceuticals, Inc.
Same institution · by research overlap
- Amanda Malone$4,368,893
Others in their field
Top investigators on “Vaginal Ring”
- Myron S Cohen · Family Health International$91,263,426
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$67,249,846
- Elizabeth Renata Brown · Fred Hutchinson Cancer Center$31,139,823
- Thomas J. Smith · Control Delivery Systems, Inc.$16,353,154
- Lisa C Rohan · Magee-Women'S Hospital Of Upmc$9,788,755
Research focus
Vaginal RingSafetyPharmaceutical PreparationsVaginaIn VivoIn VitroPreventTransmission ProcessWomanFormulationInfectionDrug KineticsPhase I Clinical TrialsCollaborationsResistanceHiv InfectionsMacacaDesignClinical TrialsLeadAids PreventionFumaratesSheepSheep Model
Grant awards (21)
Sialic acid analogs against multidrug-resistant gonorrhea$935,587
R01 · FY2025 · AI
Sialic acid analogs against multidrug-resistant gonorrhea$936,377
R01 · FY2024 · AI
A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection$886,859
R01 · FY2024 · AI · contact PI
Sialic acid analogs against multidrug-resistant gonorrhea$928,732
R01 · FY2023 · AI
A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection$890,560
R01 · FY2023 · AI · contact PI
Sialic acid analogs against multidrug-resistant gonorrhea$981,731
R01 · FY2022 · AI
A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection$904,172
R01 · FY2022 · AI · contact PI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$477,355
R33 · FY2022 · AI
Sialic acid analogs against multidrug-resistant gonorrhea$1,316,757
R01 · FY2021 · AI
A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection$877,357
R01 · FY2021 · AI · contact PI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$475,901
R33 · FY2021 · AI
A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection$914,204
R01 · FY2020 · AI · contact PI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$480,773
R33 · FY2020 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$495,740
R61 · FY2019 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$523,283
R61 · FY2018 · AI
Core B: Antiretroviral Intravaginal Ring Formulation$443,391
U19 · FY2018 · AI · contact PI
Core B: Antiretroviral Intravaginal Ring Formulation$313,747
U19 · FY2017 · AI · contact PI
Core B: Antiretroviral Intravaginal Ring Formulation$274,374
U19 · FY2016 · AI · contact PI
Core B: Antiretroviral Intravaginal Ring Formulation$375,796
U19 · FY2015 · AI · contact PI
Core B: Antiretroviral Intravaginal Ring Formulation$393,957
U19 · FY2014 · AI · contact PI
An intravaginal ring for real-time evaluation of adherence to topical vagina$211,862
R41 · FY2013 · AI · contact PI